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Despite great advances in the understanding of the genetics and pathophysiology of cys-
tic fibrosis (CF), there is still no cure for the disease. Using phosphodiesterase type 5
(PDE5) inhibitors, we and others have provided evidence of rescued F508del-CFTR traf-
ficking and corrected deficient chloride transport activity. Studies using PDE5 inhibitors
in mice homozygous for the clinically relevant F508del mutation have been conducted
with the aim of restoring F508del-CFTR protein function. We demonstrated, by measuring
transepithelial nasal potential difference in F508del mice following intraperitoneal injec-
tion of sildenafil, vardenafil, or taladafil at clinical doses are able to restore the decreased
CFTR-dependent chloride transport across the nasal mucosa. Moreover, vardenafil, but
not sildenafil, stimulates chloride transport through the normal CFTR protein. We devel-
oped a specific nebulizer setup for mice, with which we demonstrated, through a single
inhalation of PDE5 inhibitors, local activation of CFTR protein in CF. Significant potential
advantages of inhalation drug therapy over oral or intravenous routes include rapid onset of
pharmacological action, reduced systemic secondary effects, and reduced effective drug
doses compared to the drug delivered orally; this underlines the relevance and impact of
our work for translational science. More recently, we analyzed the bronchoalveolar lavage
of CF and wild-type mice for cell infiltrates and expression of pro-inflammatory cytokines
and chemokines; we found that the CFTR activating effect of vardenafil, selected as a
representative long-lasting PDE5 inhibitor, breaks the vicious circle of lung inflammation
which plays a major role in morbi-mortality in CF. Our data highlight the potential use of
PDE5 inhibitors in CF. Therapeutic approaches using clinically approved PDE5 inhibitors to
address F508del-CFTR defects could speed up the development of new therapies for CF.
Keywords: CFTR, cystic fibrosis, PDE5 inhibitors, sildenafil, vardenafil, taladafil
INTRODUCTION
Approximately 80,000 people in the world are diagnosed with Cys-
tic Fibrosis (CF), the most common, life-threatening, recessively
inherited disease in Caucasian populations. Affecting about one
newborn in every 2,500 live births, CF is due to mutations in the
CF transmembrane conductance regulator (CFTR) gene (Kerem
et al., 1989; Riordan et al., 1989) which encodes the main chlo-
ride channel expressed in epithelia. CF disease causes abnormal
mucociliary clearance mainly in the lungs, leading to a vicious cycle
of obstruction/infection/inflammation that progressively and irre-
versibly damages lung tissue and architecture. Many organs are
affected in CF but pulmonary disease is the major cause of mor-
bidity and mortality (Rowe et al., 2005; Davis, 2006). Although life
expectancy and quality of life have progressively improved over
time, there is still no cure for CF.
The most common disease allele, F508del, corresponding to
a deletion of a single phenylalanine residue at position 508 of a
single polypeptide chain of 1480 amino acids, prevents the effi-
cient folding of the CFTR protein. The F508del-CFTR protein is
correctly translated but it is retained in the endoplasmic reticu-
lum and directed toward proteosomal degradation (Lukacs et al.,
1994). As a consequence, expression of the misfolded, immature,
partly glycosylated F508del-CFTR protein at apical membranes is
reduced, leading to a loss-of-function of transepithelial chloride
transport.
Recent research in CF basic science has focused on the discovery
of pharmacological therapies directed to treat mutation-specific
changes (for review, Lubamba et al., 2012a). In the case of the
F508del-CFTR mutation, efforts have been made to correct local-
ization of the mutant protein by favoring its expression at the
apical membrane of cells. However, it has been recognized that
rescuing F508del-CFTR to the plasma membrane does not com-
pletely correct chloride transport abnormalities as it also displays
reduced channel activity (Amaral, 2004). Therefore,finding a com-
pound that also promotes CFTR channel activity would be of a
great benefit. Searching for such compounds, we and others have
demonstrated the potential of inhibitors of phosphodiesterase
type 5 (PDE5), such as sildenafil, vardenafil, and taladafil, for the
treatment of CF. Indeed, recent findings have evidenced that the
drugs, already in clinical use for the treatment of erectile dysfunc-
tion and of pulmonary arterial hypertension, are able to rescue
F508del-CFTR trafficking (Dormer et al., 2005; Robert et al.,
2008) and to improve its channel activity (Lubamba et al., 2008,
2011).
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CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
PDE activity is found in all cells, but with a distinct cellular and
subcellular distribution of the 11 mammalian isoforms (Beavo
et al., 1970). By catalyzing the hydrolysis of 3′ cyclic phosphate
bonds of adenosine and/or guanosine 3′5′ cyclic monophosphate
(cAMP and/or cGMP) the enzyme regulates the intracellular lev-
els of the second messengers. The multiple isoforms of PDEs and
their 50 or so subtypes, displaying different kinetics and regulatory
properties (Cheung, 1970; Conti, 2000; Soderling and Beavo, 2000;
Francis et al., 2001; Mehats et al., 2002), are characterized by their
specificity and sensitivity to calcium-calmodulin and their affinity
for cAMP or cGMP (Figure 1).
Eleven families of PDE have been identified in mammalian
tissues (Cheung, 1970; Conti, 2000; Soderling and Beavo, 2000;
Francis et al., 2001; Mehats et al., 2002) and are classified on
the basis of their amino acid sequences, substrate specificities,
pharmacological properties, and tissue distributions (Table 1).
PDE INHIBITORS: MAIN CHARACTERISTICS AND CLINICAL
APPLICATIONS
Inhibition of PDEs leads to increasing intracellular concentrations
of endogenous cAMP/cGMP (Bender and Beavo,2006). Therefore,
inhibition of PDE can mediate a variety of physiological mech-
anisms at different cell and organ levels. Strategies directed to
promote inhibition of PDE activity have been applied as thera-
peutic tools in a variety of lung and inflammatory disorders, such
as asthma and chronic obstructive pulmonary disease (COPD) but
also in neuronal, cardiovascular, and other conditions (Table 1).
Many selective and non-selective PDE inhibitors have been
explored as therapeutic agents. PDE1s are calcium- and
calmodulin-dependent activators or regulators (Ahn et al., 1991;
Yan et al., 1995; Loughney et al., 1996; Yu et al., 1997). Several
isoforms have been recognized exhibiting different affinities for
cAMP and cGMP. PDE1 inhibition has been investigated in treat-
ing neuronal plasticity (Medina et al., 2006; Menniti et al., 2006),
detrusor instablities and urgency incontinence (Truss et al., 2001),
memory loss (Zhang et al., 2004), reversal of the effects of early
alcohol exposure in learning performance in the water maze (Jeon
FIGURE 1 | Substrate specificity of the different families of PDE.
Although a high degree of homology has been observed within the catalytic
domain of PDEs, slight structural differences in these domains determine
the specificity of substrate of PDEs (Xu et al., 2004).
et al., 2010) and Parkinson and Alzheimer diseases (Reed et al.,
2002). It was recently demonstrated that vinpocetine has a strong
anti-inflammatory effect (Filgueiras et al., 2010; Medina, 2010).
PDE2, which metabolizes both cGMP and cAMP (Rosman
et al., 1997), is highly expressed in heart (Rivet-Bastide et al., 1997)
and brain but lower expression levels are found in a variety of
organs (Sadhu et al., 1999). PDE2 inhibitors identified so far lack
therapeutic actions (Repaske et al., 1992; Podzuweit et al., 1995;
Suvarna and O’Donnell, 2002; Boess et al., 2004; Rutten et al.,
2009).
It is well known that methylxanthines, non-selective PDEs
found in tea, coffee, and cocoa, stimulate the central nervous
system, relax the bronchial smooth muscle, and stimulate car-
diac muscle. Methylxanthines have long been used as therapeu-
tic agents in respiratory diseases (Sullivan et al., 1994; Barnes,
2003a,b,c; Bhatt-Mehta and Schumacher, 2003; Barnes and Stock-
ley, 2005; Muller and Jacobson, 2011). Indeed theophylline (1,3-
dimethylxanthine) and other methylxanthines have been used
in medical practice long before they were identified as PDE
inhibitors. Caffeine has long been used as a bronchodilating
agent. It has been perceived that theophylline has additional anti-
inflammatory properties for use in asthma or COPD, diseases
characterized by inflammatory and immune responses. Paraxan-
thine (1,7-dimethylxanthine), the primary metabolite of caffeine
(1,3,7-trimethylxanthine), acts through the ryanodine receptor to
elevate intracellular calcium concentration and increases viability
of neuronal cells in culture (Guerreiro et al., 2008). The synthesized
3-isobutyl-1-methylxanthine (IBMX) has a much higher affin-
ity for PDEs and, at low concentrations, it preferentially inhibits
cGMP-dependent over cAMP-dependent PDEs (Wells et al., 1975).
Moreover, methyxanthines are potent antagonists of adenosine
receptors (Muller and Jacobson, 2011).
PDE3 are non-selective enzymes with high affinity for both
cAMP and cGMP (Palmer and Maurice, 2000). A large number
of selective PDE3 inhibitors including milrinone, cilostamide, and
cilostazol have been identified as potential therapeutic tools for
cardiovascular diseases and asthma (Vandecasteele et al., 2001;
Nohria et al., 2003; Shin et al., 2007; Carev et al., 2010).
PDE4s have high affinity for cAMP, they are expressed in
inflammatory cells such as T and B lymphocytes, eosinophils, neu-
trophils, airway epithelial cells and endothelial cells (Tenor et al.,
1995a,b,c), cardiovascular tissues, and smooth muscles. PDE4
inhibitors have been developed for the treatment of asthma and
COPD (Essayan, 2001). Rolipram, a highly selective first genera-
tion PDE4 inhibitor, has been used for many years as a research
tool to investigate the role of PDE4. Rolipram inhibits neutrophilic
and eosinophilic inflammation; it proved to be an effective anti-
depressant, but side effects such as nausea and gastro-intestinal
disturbance terminated its clinical development (Scott et al., 1991).
Roflumilast was beneficial, as assessed by improvement in lung
function, even when added to a long acting β2 agonist or a long
acting inhaled antimuscarinic (O’Byrne and Gauvreau, 2009).
PDE5 has a higher affinity for cGMP and was identified in rat
platelets (Hamet and Coquil, 1978; Coquil et al., 1980) and rat lung
(Francis et al., 1980; Francis and Corbin, 1988). It is known to be
abundant in smooth muscle cells (Moncada and Martin, 1993)
and high expression levels have been found in pulmonary vascular
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smooth muscle, bronchial blood vessels, and airway smooth mus-
cle (Francis et al., 1980; Francis and Corbin, 1988). Recent data
have shown that PDE5 may modulate pressure-induced cardiac
hypertrophy and fibrosis (Sebkhi et al., 2003). Several compounds
that potently inhibit PDE5 have been synthesized recently, and
three of these are currently in clinical use for male erectile dys-
function (Figure 2). Sildenafil (Viagra; Pfizer Inc., USA), the first
compound of this class to be marketed, provides well-tolerated
pharmacotherapy for erectile dysfunction (Milligan et al., 2002;
Muirhead et al., 2002; Nichols et al., 2002; Ghofrani et al., 2006;
Burgess et al., 2008). Two newer selective PDE5 inhibitors, var-
denafil (Levitra; GlaxoSmithKline, UK; Klotz et al., 2001; Stark
et al., 2001; Gresser and Gleiter, 2002; Ormrod et al., 2002), and
taladafil (Cialis; Eli Lilly, US; Eardley and Cartledge, 2002; Bella
and Brock, 2003; Brock, 2003; Curran and Keating, 2003; Porst
et al., 2003; Staab et al., 2004) have the same mechanism of action,
as they specifically bind to the catalytic site of the enzyme cat-
alyzing the breakdown to 5′-GMP of cGMP, the second messenger
of the nitric oxide (NO) pathway in vascular smooth muscle cells
(Moncada and Martin, 1993). Sildenafil (under the tradename
Revatio) and taladafil (under the tradename Adcirca) have also
been approved for the treatment of ailments related to smooth
muscle tissues, such as pulmonary arterial hypertension (Sebkhi
et al., 2003; Corbin et al., 2005; Wharton et al., 2005). It has been
reported that sildenafil and vardenafil raise hippocampal cGMP
levels and improve memory in aged rats (Prickaerts et al., 2002)
and mice (Baratti and Boccia, 1999).
PDE6s display high affinity for cGMP and are expressed in the
photoreceptor outer segments of the mammalian retina, in which
they mediate transduction of the light signal into an electrical sig-
nal (Zhang et al., 2005). Dipyridamole has been described to be
a very potent cGMP-specific PDE inhibitor of visual transduction
by cGMP accumulation (Estrade et al., 1998).
PDE7s are characterized by their high affinity and selectivity for
cAMP as a substrate (Gardner et al., 2000; Hetman et al., 2000a;
Sasaki et al., 2000; Smith et al., 2003; Pitts et al., 2004; Vergne
et al., 2004; Zhang et al., 2008). Expression is abundant in T cells,
eosinophils and neutrophils, epithelial cells, vascular smooth mus-
cle cells, and lung fibroblasts (Smith et al., 2003). Several distinct
PDE7 inhibitors have been reported (Pitts et al., 2004; Vergne et al.,
2004). As PDE7 is simultaneously expressed in inflammatory cells
and in the brain highlights the potential role of PDE7 as drug
target for neuroinflammation. It has been shown that selective
PDE7 inhibition or dual PDE4/7 inhibition may provide a novel
therapeutic approach for the treatment of chronic lymphocytic
leukemia (CLL) by enhancing killing and increasing specificity for
CLL cells (Zhang et al., 2008).
PDE8s are cAMP specific, widely distributed in various tis-
sues (Glavas et al., 2001; Wang et al., 2001; Kobayashi et al., 2003;
Perez-Torres et al., 2003; Dong et al., 2006; Hayashi et al., 2007)
and abundant in testis (Vasta et al., 2006). The company Pfizer
reported on a small molecule called PF-04957325 that selectively
inhibits PDE8 at very low doses (Vang et al., 2010). PDE8-selective
inhibitors might be used to correct adrenal insufficiency, and
a PDE8 activator might be used to treat Cushing’s syndrome
(Tsai et al., 2011). It has also been shown that inhibiting PDE8
potentiates the biphasic insulin response to glucose (Dov et al.,
2008).
FIGURE 2 | Structures of the three clinically approved phosphodiesterase
type 5 inhibitors. Sildenafil, vardenafil, and tadalafil have been approved for
treatment of erectile dysfunction. Sildenafil and taladafil have also been
approved as a treatment for pulmonary arterial hypertension. Sildenafil citrate
is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-
1Hpyrazolo[4,3-d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
citrate. Vardenafil HCl is designated chemically as piperazine,
1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f ][1,2,4]triazin-2-yl)-4-
ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride. Taladafil is designated
chemically as pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione,6-(1,3-
benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-,
(6R,12aR)-.
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PDE9 is one of the most recently discovered PDE families. It
has a very high affinity for cGMP and it is expressed in a vari-
ety of tissues (Soderling et al., 1998a,b). Compared to the other
cGMP-specific PDEs, PDE9 apparently lacks the non-catalytic
cGMP-binding domain present in the cGMP-specific PDE5 and
PDE6 and also in the dually specific PDE2. BAY 73-6691, acting as
a PDE inhibitor selective for the PDE9A subtype, is a drug devel-
oped by Bayer for the treatment of Alzheimer’s disease (van der
Staay et al., 2008).
PDE10 was isolated and characterized as a dual-substrate gene
family distributed in fetal lungs and brain (Fujishige et al., 1999;
Loughney et al., 1999; Soderling et al., 1999). The finding that
striatal PDE10 mRNA and protein levels have been found to
be reduced in Huntington’s disease (Hebb et al., 2004) would
impact on the development of PDE10 agonists. Based on their
high expression levels in the brain, PDE10s have become a target
for central nervous system research, especially concerning cog-
nitive deficits related to schizophrenia and psychotic statuses.
A series of pyrazoloquinoline analogs have been synthesized
and shown to bind with high affinity to PDE10 (Yang et al.,
2012).
PDE11 are characterized by their high affinity for both cAMP
and cGMP, although kinetic characteristics for the variants are
different (Fawcett et al., 2000; Hetman et al., 2000b; Weeks et al.,
2007). BC 11–38 is a recently identified potent and selective PDE11
inhibitor (IC50= 0.28µM) with potential application for adrenal
insufficiency (Ceyhan et al., 2012).
PDE INHIBITORS AS POTENTIAL TOOLS IN THE TREATMENT
OF CYSTIC FIBROSIS
As an important second messenger signaling molecule, cAMP
controls a wide variety of eukaryotic and prokaryotic responses
to extracellular cues (Antoni, 2000). As CF is characterized by
a defective cAMP-dependent chloride conductance in epithelial
cells, it could be expected that modulating intracellular levels of
the second messenger would bring beneficial therapeutic effects
for patients with CF.
NON-SELECTIVE PDE INHIBITORS
Non-specific PDE inhibitors such as IBMX, theophylline, and
DPMX (7-methyl-1,3-dipropylxanthine) have been shown to acti-
vate normal and mutated CFTR chloride channels in epithelia
(Chappe et al., 1998). Due to impact on the cAMP pathway and
activity at low concentrations, studies have looked at the effect of
methylxanthines on the cAMP activated CFTR channel. It has been
reported that IBMX increases CFTR chloride current in Xeno-
pus oocytes expressing F508del-CFTR (Drumm et al., 1991). In
nasal bronchial epithelial tissues expressing the mutant F508del-
CFTR, treatment with IBMX associated with a potent adeny-
late cyclase agonist, forskolin was unable to stimulate chloride
efflux (Grubb et al., 1993). However, stably transfected F508del-
CFTR cells (Haws et al., 1996) showed a sevenfold increase in
cAMP levels following IBMX treatment but not after cyclopentyl-
1,3-dipropylxanthine (CPX), another non-specific PDE inhibitor.
Interestingly both IBMX and CPX potentiated the effect of
forskolin on CFTR-mediated efflux of 125I by 2.5-fold (Haws et al.,
1996). A potentiation by IBMX of prostaglandin E (PGE)-induced
bicarbonate secretion has been reported in the rat duodenum
in vivo (Takeuchi et al., 1997; Aoi et al., 2004).
SELECTIVE PDE INHIBITORS
PDE inhibitors increase cAMP by inhibiting one or more enzymes
involved in cAMP degradation. Cyclic AMP-activated PKA medi-
ates phosphorylation of CFTR and increases the open probability
of the CFTR channel. PDE3 inhibitors, amrinone, and milrinone,
also cause vasodilation, which may be beneficial for CF airways.
Drumm et al. showed that inhibiting PDE had a larger effect on
CFTR activation than have adenylate cyclase stimulants (Kelley
et al., 1995). Using airway epithelial cell lines expressing wild-
type CFTR, Calu-3, and 16HBE cells, it has been found that, at
100µM concentrations, milrinone, or amrinone applied in the
absence of adenylate cyclase activators, stimulate chloride efflux
by 13.7-fold (Kelley et al., 1995). No effect on chloride efflux was
found under stimulation with IBMX, rolipram, or dipyridamole.
The increase of channel efflux by PDE3 inhibitor, amrinone, or
milrinone, was not associated with a significant rise in cAMP con-
centrations but it was inhibited by protein kinase A inhibitors
(H-8 and Rp-cAMPS), suggesting that it might work through a
more distal signal. Kelley et al. (1996) also looked at endogenous
CFTR in transformed nasal polyp tissue of patients homozygous
for F508del (CF-T43). They found that, when administered in
the presence of a β-agonist (isoproterenol) and protein kinase A
activator, milrinone, and amrinone, at 100µM concentrations,
increased chloride efflux by 19–61% from baseline. Mice homozy-
gous for F508del-CFTR were administered with a combination of
milrinone (100µM) and forskolin (10µM; Kelley et al., 1997).
This combination of drugs resulted in an increased magnitude of
the nasal potential difference. The implications of this study are
exciting; but the effect was confirmed in mice but not in humans
(Smith et al., 1999).
It has been shown that CFTR has a major role in the regulation
of duodenal bicarbonate secretion (Hogan et al., 1997). Further-
more, O’Grady et al. (2002) showed that both PDE1 and PDE3
are involved in the activation of CFTR in T84 cells and human
colonic epithelial cells. Hayashi et al. (2007) suggested that PDE1
and PDE3 are involved in the regulation of duodenal bicarbonate
secretion and that the response to PGE2 is associated with both
PDE1 and PDE3, while the response to NO is mainly modulated
by PDE1 (Hayashi et al., 2007). McPherson et al. (1999) showed
that a selective cyclic nucleotide PDE5 inhibitor partially corrected
defective l-adrenergic stimulation of mucin secretion in CFTR
antibody-inhibited submandibular cells. The PDE5 inhibitor did
not increase cAMP levels, nor did it potentiate isoproterenol-
induced cAMP rise (McPherson et al., 1999). Of note,Dormer et al.
(2005) demonstrated that the PDE5 inhibitor sildenafil also acts
as a pharmacological chaperone. Because sildenafil is approved
for clinical use, they speculated that their data might speed up the
development of new therapies for CF (Dormer et al., 2005).
COMPARISON OF THE PDE5 INHIBITORS
There are distinct differences between the three clinically approved
PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, regard-
ing their selectivity and specificity for PDE inhibition, with
consequences on safety profile but also on biopharmaceutic and
www.frontiersin.org September 2012 | Volume 3 | Article 167 | 5
Noel et al. PDE5 inhibitors for CF
pharmacokinetic disparities that largely affect efficacy of the com-
pounds (Klotz et al., 2001; Gresser and Gleiter, 2002; Milligan
et al., 2002; Muirhead et al., 2002; Nichols et al., 2002; Burgess
et al., 2008). Sildenafil and vardenafil are very similar in terms of
chemical structure, whereas tadalafil, with a methyldione struc-
ture, differs markedly (Figure 2). These chemical properties are
also reflected in similarities and dissimilarities of their clinical
pharmacokinetics.
PDE5 inhibitors are rapidly absorbed after oral administration,
with peak concentrations reached slightly earlier for vardenafil
compared to sildenafil and tadalafil (Klotz et al., 2001; Gresser and
Gleiter, 2002; Milligan et al., 2002; Muirhead et al., 2002; Nichols
et al., 2002; Burgess et al., 2008). Although no clear concentration-
effect relationships have been established for any of the three PDE5
inhibitors, rapid absorption is considered essential for a rapid
onset of efficacy. Administration of a high-fat meal had no sig-
nificant effect on the rate and extent of absorption of tadalafil but
decreased the rate of absorption for sildenafil and vardenafil. All
three drugs are lipophilic and have a volume of distribution larger
than the volume of total body water, indicating tissue uptake and
binding. Furthermore, the three compounds are highly protein
bound, with free plasma concentration fractions of only 4–6%.
The major route of elimination for all PDE5 inhibitors is
hepatic metabolism, with renal excretion of unchanged drug
accounting for 1% or less of the elimination pathways. Based on
their relatively high systemic clearance after intravenous admin-
istration, sildenafil, and vardenafil can be classified as non-
restrictively cleared drugs with intermediate to high hepatic
extraction ratio. The relatively comparable distribution volumes
together with the substantial differences in systemic clearance
among the PDE5 inhibitors result in distinct differences of the
elimination half-life, 3–5 h for sildenafil and vardenafil compared
to 17.5 h for tadalafil. Tadalafil, however, has been detected in
plasma even 5 days after oral administration, in line with its long
half-life. This suggests the possibility of accumulation if taken reg-
ularly and in short intervals, which may result in an increased risk
of side effects with excessive use.
PDE5 INHIBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
So far, many efforts have been focused on CFTR pharmacother-
apy to target the abnormal protein pharmacologically by various
approaches such as direct correction of stop codon mutations,
CFTR channel activation, or trafficking defects. High-throughput
screening has been used to identify molecules that increase
F508del-CFTR activity (Pedemonte et al., 2005; Van Goor et al.,
2006; Carlile et al., 2007). Such molecules have been categorized
according to whether they improve the folding/cellular processing
defect (correctors) or increase the responsiveness of F508del-
CFTR channels already present in the membrane to cAMP activa-
tion (potentiators). Sildenafil has been initially shown to correct
F508del-CFTR processing when used at supratherapeutic doses
(Dormer et al., 2005).
PDE5 INIBITORS CORRECT TRANSEPITHELIAL CHLORIDE TRANSPORT
IN CYSTIC FIBROSIS: PARENTERAL ADMINISTRATION
To test the hypothesis that PDE5 inhibitors sildenafil, vardenafil,
and taladafil, when applied at therapeutic doses, are able to restore
transepithelial ion transport abnormalities of the F508del-CFTR
protein, we have conducted experimental studies (Lubamba et al.,
2008, 2011) in CF mice homozygous for the F508del mutation
(van Doorninck et al., 1995) and in their corresponding wild-
type homozygous normal mice. The F508del-CFTR mouse model
has been chosen because F508del is the most common and one
of the most severe CF mutations and because the mouse model
recapitulates, although with different degrees of severity in the
different systems, the human disease phenotype. Epithelia of the
F508del-CF mouse model are characterized by defective electrolyte
transport, and Pseudomonas aeruginosa lipopolysaccharide (LPS)
exposure mimics several aspects of CF airway epithelial inflamma-
tion such as increased pro-inflammatory cytokines, most notably
interleukin (IL)-8, IL-6, and Tumor Necrosis Factor (TNF)-α, and
the predominant neutrophil infiltration.
In our protocols, CFTR function has been assessed in vivo by
measuring the transepithelial nasal potential difference, a diag-
nostic technique that has been more recently used as an index
of therapeutic efficacy in novel fundamental therapies, either
in animal models (Lubamba et al., 2008, 2009, 2011) or in CF
patients (Sermet-Gaudelus et al., 2010; Leonard et al., 2012a,b).
Our results provide clear evidence that intraperitoneal injection
of PDE5 inhibitors (Figure 3), at therapeutic doses, to F508del-
CF mice interact with CFTR, propping open the mutant protein
to allow a normal flow of chloride ions across the epithelium
of nasal mucosa, thereby restoring the decreased or even abol-
ished CFTR-dependent chloride transport (Lubamba et al., 2008).
In F508del mice, but not in cftr knockout mice, the chloride
conductance, evaluated by perfusing the nasal mucosa with a
chloride-free solution in the presence of amiloride (to inhibit
sodium entry through the epithelial sodium channel ENaC) and
with forskolin, is corrected 1 h after a single sildenafil adminis-
tration (Figure 4A). A more prolonged effect, persisting for at
least 24 h, is observed with vardenafil (Figure 4B). Moreover, var-
denafil, but not sildenafil, is able to stimulate chloride transport
associated with normal wild-type CFTR protein (Figure 4B). The
forskolin response is increased after treatment with sildenafil or
vardenafil in wild-type and in F508del mutant animals. In F508del
mice, the chloride conductance in the presence of 200µM DIDS
(4-4′-diisothiocyanostilbene-2,2′-disulphonic acid), an inhibitor
of alternative chloride channels, was much higher after sildenafil
injection than following placebo treatment. This observation, in
addition to the finding that no activating effect of chloride trans-
port can be observed after treatment with PDE5 inhibitors in
animals knockout for the CFTR protein, indicates that the action
of PDE5 inhibitors on chloride transport across the respiratory
epithelium involves F508del-CFTR and not a CFTR bypass chan-
nel. No effect on the sodium conductance was detected in any
group of animals.
PDE5 INHIBITORS CORRECT TRANSEPITHELIAL CHLORIDE TRANSPORT
IN CYSTIC FIBROSIS: INHALATIONAL ADMINISTRATION
More recently, animal studies have shown that nebulizing F508del-
CF mice with any of the PDE5 inhibitors sildenafil, vardenafil, or
taladafil led to correction of the nasal chloride transport (Lubamba
et al., 2011). Correction is largest with taladafil and smallest, but
still highly significant, with sildenafil. The effect of vardenafil, but
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FIGURE 3 | Representative tracings of nasal potential difference (PD)
measurements in wild-type (WT) and F508del-CF (CF) mice 24 h after
placebo (saline) or vardenafil (single i.p. dose of 0.14 mg/kg body
weight). Tracings show sequential response of the nasal surface to perfusion
successively with basal solution, basal solution with 10−4 M amiloride (amil),
chloride-free solution plus amiloride (0 Cl), and chloride-free solution with
amiloride plus 10–5 M forskolin (forskolin). Arrows indicate change of
solutions. As illustrated, basal values and amiloride response are not
influenced by vardenafil treatment. However, chloride secretion (difference
between values obtained at the end of the test and the end of the amiloride
phase) is restored in CF animals and the effect lasts at least 24 h after
vardenafil treatment (Lubamba et al., 2008).
not sildenafil, lasts at least 8 h after a single inhaled therapeutic
dose. These findings clearly identify the inhalational route as a
potential therapy for PDE5 inhibitors in CF which is clinically rel-
evant taking into account the cost of systemic side effects of the
drugs (Dalby and Suman, 2003).
Consistent with our results, it has recently been demonstrated
that the inhalation route of administration for vardenafil is asso-
ciated with an acceptable safety profile. Apart from brief coughing
on inspiration, no clinically significant changes in blood pressure
or heart rate and no serious adverse events were recorded (Berry
et al., 2009). Inhalation drug therapy has several potential advan-
tages over oral and intravenous routes, including rapid onset of
pharmacological action, minimized systemic adverse effects and
reduced effective drug doses compared to the same drug delivered
orally (Berry et al., 2009); this greatly highlights the impact of our
work for translational science.
PDE5 INHIBITORS ATTENUATE EXAGGERATED INFLAMMATORY
RESPONSES IN CYSTIC FIBROSIS
Another important goal of mutation-specific CF treatment is
attenuation of exaggerated lung inflammatory responses (Legssyer
et al., 2006; Gavilanes et al., 2009; Meyer et al., 2009). As lung
inflammation plays a major role in morbi-mortality in CF, iden-
tifying a therapeutic strategy that combines ability to correct the
basic ion transport defect and to reduce dysregulated inflamma-
tory responses is very exciting and promising. It has been reported
that sildenafil reduces neutrophil lung infiltration in murine air-
ways infected with P. aeruginosa (Poschet et al., 2007). In addi-
tion, toxicological studies have shown that sildenafil pretreatment
attenuates acrolein-triggered airway inflammation associated with
mucin overproduction (Wang et al., 2009).
More recently, we have found that vardenafil, selected as a rep-
resentative PDE5 inhibitor for its longer-lasting CFTR activating
effect, modulates the vicious circle of lung inflammation and
attenuates the expression of pro-inflammatory cytokines and
chemokines and cell infiltrates in the bronchoalveolar lavage
(BAL) of CF and wild-type mice (Lubamba et al., 2012b).
Intraperitoneal administration of a single pharmacological dose
(0.14 mg/kg body weight) of vardenafil is followed by a reduc-
ing response in cell infiltrate and in the biosynthesis of several
biomarkers of the inflammatory response. Most notably, levels of
CCL-2 (chemokine C-C motif ligand), a cytokine playing a key role
in the contribution of macrophages in the inflammatory response
(Meyer et al., 2009), are significantly reduced in the BAL fluid after
vardenafil treatment, particularly in CF animals (Figure 5).
The mechanism of action of vardenafil as an anti-inflammatory
agent in CF as well as the target-effector cells involved in these
responses are under investigation by our group. Altogether, our
data indicate that PDE5 inhibitors have a strong therapeutic poten-
tial for treating CF. A clinical trial aimed at investigating the safety
and efficacy of sildenafil in CF lung disease is currently listed on
www.clinicaltrials.gov (NCT00659529).
PERSPECTIVE FUTURE RESEARCH
Beside the clinical application for erectile dysfunction and for pul-
monary arterial hypertension, a growing body of research has con-
firmed putative beneficial effects of PDE5 inhibitors in CF. Recent
studies conducted in F508del and in wild-type CFTR expressing
Xenopus laevis oocytes and human bronchial epithelial cells have
indicated that sildenafil acts as a corrector and as a potentiator of
the mutant and wild-type protein by distinct cGMP-independent
and cGMP-dependent mechanisms respectively (Leier et al., 2012).
While in X. laevis oocytes, low (1.5µmol/l) doses were required
to rescue F508del-CFTR function and cell membrane localiza-
tion, suprapharmacological doses roughly 120 times larger than
those commonly used for the treatment of erectile dysfunction
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FIGURE 4 | Effect of parenteral (i.p.) administration of sildenafil (A;
0.7 mg/kg body weight) and of vardenafil (B; 0.14 mg/kg body weight)
on CFTR-dependent chloride secretion assessed by means of the nasal
potential difference (PD) in wild-type (WT) and F508del-CF mice.
Vardenafil stimulates chloride secretion of the wild-type CFTR. The correcting
effect of vardenafil lasts at least 24 h. Data are expressed as mean±SEM of
14–15 placebo treated animals and six animals treated with PDE5 inhibitors
(Lubamba et al., 2008).
were needed to achieve the same correcting effects in human
bronchial epithelial cells (Leier et al., 2012). In this perspective,
adverse drug effects including flushing, headache, and other car-
diovascular effects could compromise the potential use of PDE5
inhibitors in CF.
Attempts should therefore be made either to achieve
chemical modifications of PDE5 inhibitors with enhanced
biochemical potency and selectivity or to allow inhala-
tional therapy of the drugs. A structural analog of silde-
nafil, KM11060, designated chemically as 7-chloro-4-{4-[4-
chlorophenyl)sulfonyl]piperazino}quinoline, has been recently
identified as a novel potent corrector of the F508del-CFTR traf-
ficking defect (Robert et al., 2008). F508del-CFTR trafficking was
partially restored and maturation of the mutant protein was sig-
nificantly increased in baby hamster kidney cells treated with low
doses for a short duration (10 nM for 24 h or 10µM for 2 h) of the
compound (Robert et al., 2008). Since the morbi-mortality of CF
is mostly related with respiratory manifestations and an accept-
able safety profile with no serious adverse events was recorded
when vardenafil was applied by inhalational route (Berry et al.,
2009), topical airway deposition of PDE5 inhibitors (Lubamba
et al., 2011) should be considered in future human studies. As a
matter of fact, inhalation drug therapy has several potential advan-
tages over oral and intravenous routes, including rapid onset of
pharmacological action, minimized systemic adverse effects, and
reduced effective drug doses compared to the same drug delivered
orally (Dalby and Suman, 2003).
CONCLUSION
Despite great advances in the understanding of the genetics and
pathophysiology of the disease, there is still no cure for CF
and existing therapies have mainly aimed at alleviating clinical
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FIGURE 5 | Anti-inflammatory effect of in vivo treatment, by i.p.
injection, of a single therapeutic dose of vardenafil (vard) to wild-type
(A) and F508del-CF (B) mice on the inflammatory response induced by
lipopolyssaccharide from P. aeruginosa (LPS). Biosynthesis of CCL-2 is
significantly reduced in the bronchoalveolar lavage of vardenafil-treated CF
and non-CF animals (Lubamba et al., 2012b).
symptoms. Recent experimental evidence has highlighted the
potential of PDE5 inhibitors, sildenafil, vardenafil, and taladafil,
as therapeutic agents in CF. As the drugs are able to correct
the basic transepithelial ion transport abnormalities and to limit
exaggerated inflammatory responses related to the presence of
F508del-CFTR protein, they can represent promising compounds
for fundamental pharmacotherapy in CF. Since the drugs are
in clinical use, therapeutic approaches to address F508del-CFTR
defects by PDE5 inhibitors can be considered as a “low-hanging
fruit”strategy in the drug discovery tree which could speed up their
development as CF therapeutics, as compared to other agents that
are under investigation only for CF therapy and for which further
exploratory studies are needed before being streamed toward clin-
ical testing. In summary, CFTR correction with PDE5 inhibitors is
a promising therapeutic approach based on functional correction
of F508del-CFTR activity and on a possible anti-inflammatory
action in F508del mice. The effects of these compounds on other
CF mutation classes remain to be assessed. The routes for admin-
istration should also be further explored, and aerosolized delivery
of PDE5 inhibitors should be considered.
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